Annual report pursuant to Section 13 and 15(d)

License Agreements (Details Textual)

v3.19.1
License Agreements (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
May 11, 2015
May 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Mar. 31, 2015
Sep. 30, 2018
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Neupharma [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Payment of Upfront Fees         $ 1,000,000        
Reimbursement Of Cost Recognized As Revenue             $ 35,000 $ 600,000  
Neupharma [Member] | Additional Sales Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum Potential Milestone Payments             40,000,000    
Neupharma [Member] | Clinical and Development Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum Potential Milestone Payments             40,000,000    
Neupharma [Member] | Regulatory Approvals To Commercialize The Products [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum Potential Milestone Payments             22,500,000    
Dana-Farber [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Shares Issued, Price Per Share $ 0.065                
Stock Issued During Period, Shares, Issued for Services 500,000     136,830          
Stock Issued During Period, Value, Issued for Services $ 32,500     $ 600,000          
Payment of Upfront Fees         1,000,000        
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 5.00%                
Cash In Exchange For Common Stock $ 10,000,000                
Payment For Non refundable Milestone payments           $ 1,000,000      
Maintenance Fee             50,000    
Dana-Farber [Member] | First Commercial Sale Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method, Payments Due             21,500,000    
Maximum Potential Milestone Payments             21,500,000    
Dana-Farber [Member] | Additional Sales Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method, Payments Due             60,000,000    
Maximum Potential Milestone Payments             60,000,000    
Teva Pharmaceutical Industries Ltd [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Payment of Upfront Fees     $ 500,000            
Jubilant Biosys Ltd [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Payment of Upfront Fees                 $ 2,000,000
Revenue Recognition, Milestone Method, Revenue Recognized             $ 400,000 1,000,000  
Research and Development Cost, Shared Percentage             50.00%    
Non-Refundable Milestone Payment               400,000  
Proceeds from Upfront Fees   $ 1,000,000              
Jubilant Biosys Ltd [Member] | Clinical and Development Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum Potential Milestone Payments             $ 89,000,000    
Jubilant Biosys Ltd [Member] | Regulatory Approvals To Commercialize The Products [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum Potential Milestone Payments             59,500,000    
Jubilant Biosys Ltd [Member] | Five Regulatory Approvals And First Commercial Sales [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method, Payments Due             61,700,000    
Jubilant Biosys Ltd [Member] | Sale Millstone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method, Payments Due             89,000,000    
Maximum Potential Milestone Payments             89,000,000    
Jubilant Biosys Ltd [Member] | Clinical Development and Regulatory Milestones [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method, Payments Due             87,200,000    
Adimab LLC [Member] | Clinical and Development Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum Potential Milestone Payments             7,100,000    
Adimab LLC [Member] | Regulatory Approvals To Commercialize The Products [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum Potential Milestone Payments             4,800,000    
Collaboration Agreement With TGTX [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition, Milestone Method, Revenue Recognized             3,000,000 $ 100,000  
Proceeds from Upfront Fees         $ 500,000        
Collaboration Agreement With TGTX [Member] | Clinical and Development Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method, Payments Due             7,000,000    
Collaboration Agreement With TGTX [Member] | Commercial Sales In Specified Territories [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method, Payments Due             14,500,000    
Sublicense Agreement with TGTX [Member] | Clinical and Development Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method, Payments Due             $ 25,500,000